Dopamine D3 receptor antagonists
View Patent ↗The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.
1. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is:
2. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
3. A method of modulating dopamine D 3 receptors in a mammal in need thereof, the method comprising administering to the mammal an effective amount of the compound of claim 1 to modulate the dopamine D 3 receptors.
4. The method of claim 3 , wherein the method of modulating dopamine D 3 receptors is a method for treating Parkinson's disease; neuroleptic-induced parkinsonism; tardive dyskinesia; depression; anxiety; a cognitive impairment; Alzheimer's disease; an eating disorder; a sexual dysfunction; a sleep disorder; emesis; a movement disorder; obsessive-compulsive disorder; amnesia; aggression; autism; vertigo; dementia; a circadian rhythm disorder; a gastric motility disorder, or a gambling disorder.
5. A method for treating a psychotic condition in a mammal in need thereof, the method comprising administering to the mammal an effective amount of the compound of claim 1 to treat the psychotic condition.
6. A method for treating opioid use disorder in a mammal in need thereof, the method comprising administering to the mammal an effective amount of the compound of claim 1 to treat the opioid use disorder.
7. A method for treating schizophrenia in a mammal in need thereof, the method comprising administering to the mammal an effective amount of the compound of claim 1 to treat the schizophrenia.
8. A method of treating a substance-related disorder in a mammal in need thereof, the method comprising administering to the mammal an effective amount of the compound of claim 1 to treat the substance-related disorder.
9. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is:
10. A pharmaceutical composition comprising the compound of claim 9 and a pharmaceutically acceptable carrier.
11. A method of modulating dopamine D 3 receptors in a mammal in need thereof, the method comprising administering to the mammal an effective amount of the compound of claim 9 to modulate the dopamine D 3 receptors.
12. The method of claim 11 , wherein the method of modulating dopamine D 3 receptors is a method for treating Parkinson's disease; neuroleptic-induced parkinsonism; tardive dyskinesia; depression; anxiety; a cognitive impairment; Alzheimer's disease; an eating disorder; a sexual dysfunction; a sleep disorder; emesis; a movement disorder; obsessive-compulsive disorder; amnesia; aggression; autism; vertigo; dementia; a circadian rhythm disorder; a gastric motility disorder, or a gambling disorder.
13. A method for treating a psychotic condition in a mammal in need thereof, the method comprising administering to the mammal an effective amount of the compound of claim 9 to treat the psychotic condition.
14. A method for treating opioid use disorder in a mammal in need thereof, the method comprising administering to the mammal an effective amount of the compound of claim 9 to treat the opioid use disorder.
15. A method for treating schizophrenia in a mammal in need thereof, the method comprising administering to the mammal an effective amount of the compound of claim 9 to treat the schizophrenia.
16. A method of treating a substance-related disorder in a mammal in need thereof, the method comprising administering to the mammal an effective amount of the compound of claim 9 to treat the substance-related disorder.
17. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is:
18. A pharmaceutical composition comprising the compound of claim 17 and a pharmaceutically acceptable carrier.
19. A method of modulating dopamine D 3 receptors in a mammal in need thereof, the method comprising administering to the mammal an effective amount of the compound of claim 17 to modulate the dopamine D 3 receptors.
20. The method of claim 19 , wherein the method of modulating dopamine D 3 receptors is a method for treating Parkinson's disease; neuroleptic-induced parkinsonism; tardive dyskinesia; depression; anxiety; a cognitive impairment; Alzheimer's disease; an eating disorder; a sexual dysfunction; a sleep disorder; emesis; a movement disorder; obsessive-compulsive disorder; amnesia; aggression; autism; vertigo; dementia; a circadian rhythm disorder; a gastric motility disorder, or a gambling disorder.
21. A method for treating a psychotic condition in a mammal in need thereof, the method comprising administering to the mammal an effective amount of the compound of claim 19 to treat the psychotic condition.
22. A method for treating opioid use disorder in a mammal in need thereof, the method comprising administering to the mammal an effective amount of the compound of claim 19 to treat the opioid use disorder.
23. A method for treating schizophrenia in a mammal in need thereof, the method comprising administering to the mammal an effective amount of the compound of claim 19 to treat the schizophrenia.
24. A method of treating a substance-related disorder in a mammal in need thereof, the method comprising administering to the mammal an effective amount of the compound of claim 19 to treat the substance-related disorder.
25. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is:
26. A pharmaceutical composition comprising the compound of claim 25 and a pharmaceutically acceptable carrier.
27. A method of modulating dopamine D 3 receptors in a mammal in need thereof, the method comprising administering to the mammal an effective amount of the compound of claim 25 to modulate the dopamine D 3 receptors.
28. The method of claim 27 , wherein the method of modulating dopamine D 3 receptors is a method for treating Parkinson's disease; neuroleptic-induced parkinsonism; tardive dyskinesia; depression; anxiety; a cognitive impairment; Alzheimer's disease; an eating disorder; a sexual dysfunction; a sleep disorder; emesis; a movement disorder; obsessive-compulsive disorder; amnesia; aggression; autism; vertigo; dementia; a circadian rhythm disorder; a gastric motility disorder, or a gambling disorder.
29. A method for treating a psychotic condition in a mammal in need thereof, the method comprising administering to the mammal an effective amount of the compound of claim 25 to treat the psychotic condition.
30. A method for treating opioid use disorder in a mammal in need thereof, the method comprising administering to the mammal an effective amount of the compound of claim 25 to treat the opioid use disorder.
31. A method for treating schizophrenia in a mammal in need thereof, the method comprising administering to the mammal an effective amount of the compound of claim 25 to treat the schizophrenia.
32. A method of treating a substance-related disorder in a mammal in need thereof, the method comprising administering to the mammal an effective amount of the compound of claim 25 to treat the substance-related disorder.
33. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is:
34. A pharmaceutical composition comprising the compound of claim 33 and a pharmaceutically acceptable carrier.
35. A method of modulating dopamine D 3 receptors in a mammal in need thereof, the method comprising administering to the mammal an effective amount of the compound of claim 33 to modulate the dopamine D 3 receptors.
36. The method of claim 35 , wherein the method of modulating dopamine D 3 receptors is a method for treating Parkinson's disease; neuroleptic-induced parkinsonism; tardive dyskinesia; depression; anxiety; a cognitive impairment; Alzheimer's disease; an eating disorder; a sexual dysfunction; a sleep disorder; emesis; a movement disorder; obsessive-compulsive disorder; amnesia; aggression; autism; vertigo; dementia; a circadian rhythm disorder; a gastric motility disorder, or a gambling disorder.
37. A method for treating a psychotic condition in a mammal in need thereof, the method comprising administering to the mammal an effective amount of the compound of claim 33 to treat the psychotic condition.
38. A method for treating opioid use disorder in a mammal in need thereof, the method comprising administering to the mammal an effective amount of the compound of claim 33 to treat the opioid use disorder.
39. A method for treating schizophrenia in a mammal in need thereof, the method comprising administering to the mammal an effective amount of the compound of claim 33 to treat the schizophrenia.
40. A method of treating a substance-related disorder in a mammal in need thereof, the method comprising administering to the mammal an effective amount of the compound of claim 33 to treat the substance-related disorder.